Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6916941 | ABBVIE | Crystalline composition containing escitalopram |
Aug, 2022
(1 year, 8 months ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7420069 | ABBVIE | Crystalline composition containing escitalopram |
Aug, 2022
(1 year, 8 months ago) | |
US6916941 (Pediatric) | ABBVIE | Crystalline composition containing escitalopram |
Feb, 2023
(1 year, 2 months ago) | |
US7420069 (Pediatric) | ABBVIE | Crystalline composition containing escitalopram |
Feb, 2023
(1 year, 2 months ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population(NPP) | May 12, 2026 |
Market Authorisation Date: 14 August, 2002
Treatment: NA
Dosage: TABLET;ORAL